Costs and efficacy of a short-stay concept intervention in end phase Parkinson's disease. A comparison between 'regular' care and a short-stay concept.
Completed
- Conditions
- intervention 'within the Parkinsonpopulation10028037
- Registration Number
- NL-OMON34534
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
• Diagnosis of Parkinson's disease using the UK Brain Bank criteria
• Patients who are no longer able to function at home by a combination of motor,
cognition or behavioural problems (Hoehn and Yahr stadium III en IV)
• Family member or caregiver is available to give adequate information about the
functioning of the patient.
• He patient is able to speak intelligible.
• Written informed consent have to be present (patient or legal representative)
Exclusion Criteria
- Parkinsonism
- MSA
- PS
- absence of comorbidity
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are affected by short-stay interventions in end-phase Parkinson's disease compared to standard care?
How does short-stay care compare to standard care in managing motor and non-motor symptoms in advanced Parkinson's?
Are there specific biomarkers that predict response to short-stay palliative care in Parkinson's disease patients?
What adverse events are associated with short-stay care models in end-phase Parkinson's disease management?
How does the short-stay concept in Parkinson's care compare to other non-pharmacological palliative approaches?